GlobeNewswire·Jan 29, 2026, 8:30 AM ET

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YDES

YD Bio Limited (NASDAQ: YDES) signed a binding Letter of Intent on January 20, 2026, to acquire all shares, assets, & business of Taiwan-based Safe Save Medical Cell Sciences & Technology Co., Ltd. (SSMC).
The acquisition aims to integrate SSMC's proprietary Autologous Dendritic Cells/Tumor Antigens (ADCTA) technology into YD Bio's portfolio to create an end-to-end biotechnology ecosystem.
SSMC is advancing Phase III clinical trials for autologous dendritic cell immunocell therapy targeting glioblastoma & other solid tumors including ovarian, breast, lung, colorectal, & pancreatic cancers.
The total consideration for the transaction is NT$839,832,000 (approximately US$26.87 million), payable via a combination of newly issued YD Bio shares & cash.
Specific shareholders holding more than 10% of SSMC, including founder Mr. Yang Wen-Guang, will receive new YD Bio shares through a share swap, while general shareholders may choose cash or shares.
New shares issued under the agreement are subject to lock-up periods of six months for general shareholders & one year for specific shareholders in compliance with U.S. securities regulations.
The transaction requires customary closing conditions, including due diligence completion by March 20, 2026, corporate restructuring of SSMC, & the absence of material adverse changes.
Closing is anticipated within thirty days after the due diligence process concludes, pending satisfaction of all conditions precedent.
This deal follows YD Bio's recent merger with EG BioMed to integrate DNA-methylation-driven AI platforms for cancer diagnostics.
SSMC, established in 2011, has collaborated with nine medical centers & hospitals in Taiwan to apply its immunotherapy to patients with Stage IV solid tumors & those unresponsive to standard treatments.